当前位置: X-MOL 学术Clin. Cancer Res. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Crizotinib in ROS1 and MET Deregulated NSCLC--Letter
Clinical Cancer Research ( IF 10.0 ) Pub Date : 2020-04-01 , DOI: 10.1158/1078-0432.ccr-19-3740
Marcel Wiesweg 1, 2 , Martin Schuler 1, 2, 3 , Hans-Ulrich Schildhaus 4
Affiliation  

In the METROS trial, Landi and colleagues evaluated the efficacy of crizotinib in advanced non–small cell lung cancer (NSCLC) harboring ROS1 rearrangements or MET dysregulation ([1][1]). A total of 505 patients were screened and 10 patients entered the trial with cancers harboring MET exon 14

中文翻译:

克唑替尼在ROS1和MET失控的NSCLC中的作用

在METROS试验中,Landi及其同事评估了克唑替尼在具有ROS1重排或MET失调的晚期非小细胞肺癌(NSCLC)中的疗效([1] [1])。总共筛选了505位患者,其中10位患者患有MET外显子14癌
更新日期:2020-04-01
down
wechat
bug